Advances in tumor-infiltrating lymphocytes as predictors of immunotherapy efficacy in non-small cell lung cancer
10.12354/j.issn.1000-8179.2025.20250512
- VernacularTitle:肿瘤浸润淋巴细胞与非小细胞肺癌免疫治疗疗效预测相关的研究进展
- Author:
Xu MENGFAN
1
;
Liang XINJUN
1
Author Information
1. 华中科技大学同济医学院附属湖北肿瘤医院腹部肿瘤内科(武汉市 430079)
- Publication Type:Journal Article
- Keywords:
tumor-infiltrating lymphocytes(TILs);
non-small cell lung cancer(NSCLC);
immunotherapy;
prognosis;
biomarker
- From:
Chinese Journal of Clinical Oncology
2025;52(13):688-691
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer(NSCLC)is the most common type of lung cancer,accounting for more than 80%of all cases.Despite recent advances in the diagnosis and treatment of NSCLC,the prognosis of patients remains poor,with a five-year survival rate of only 15%.Currently,immune checkpoint inhibitors(ICIs)have been approved for lung cancer treatment.Although they exhibit advantages such as high efficacy,durability,and low toxicity,only a small subset of NSCLC patients derives sustained benefits from immunotherapy.With the grow-ing attention to the prognostic role of tumor-infiltrating lymphocytes(TILs)in NSCLC,the search for more effective prognostic biomarkers has become a research priority.This review systematically analyzes the mechanisms,clinical evidence,and evaluation methods of TILs in pre-dicting immunotherapy responses in NSCLC,aiming to provide references for future research and clinical applications.
